AVEO Pharmaceuticals, Inc.  

(Public, NASDAQ:AVEO)   Watch this stock  
Find more results for AVEO
May 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.61 - 3.50
Open     -
Vol / Avg. 0.00/5.23M
Mkt cap 110.14M
P/E     -
Div/yield     -
EPS -1.09
Shares 55.07M
Beta 1.02
Inst. own 29%
Aug 10, 2015
Q2 2015 Aveo Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 7, 2015
Q1 2015 Aveo Pharmaceuticals Inc Earnings Release
Mar 6, 2015
AVEO Oncology Biomarker Analysis from Phase 2 Clinical Study of Tivozanib in Patients with Advanced Colorectal Cancer - Webcast
Mar 6, 2015
Q4 2014 Aveo Pharmaceuticals Inc Earnings Call
Mar 6, 2015
Q4 2014 Aveo Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -8114.93% -291.01%
Operating margin -7573.88% -278.37%
EBITD margin - -179.34%
Return on average assets -72.29% -48.61%
Return on average equity -247.82% -116.49%
Employees 57 -
CDP Score - -


650 E Kendall St
CAMBRIDGE, MA 02142-4200
United States - Map
+1-617-2995000 (Phone)
+1-617-9954995 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering and developing therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. The Company’s Human Response Platform (HRP) provides insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. This platform was designed to overcome many of the limitations of traditional approaches to modeling human cancer. The Company’s product candidates include AV-203, Ficlatuzumab, Tivozanib and AV-380. AV-203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin-1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF), inhibitory antibody. AV-380 is for treatment of cachexia. Tivozanib is a potent, selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).

Officers and directors

Tuan Ha-Ngoc Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Michael P. Bailey President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Keith S. Ehrlich CPA Chief Financial Officer
Age: 64
Bio & Compensation  - Reuters
Michael N. Needle M.D. Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Henri A. Termeer Lead Out Side Director
Age: 69
Bio & Compensation  - Reuters
Kenneth M. Bate Independent Director
Age: 64
Bio & Compensation  - Reuters
Anthony B. Evnin Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Raju S. Kucherlapati Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert C. Young M.D. Independent Director
Age: 75
Bio & Compensation  - Reuters